4 papers
Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid drugs in Alzheimer's disease: a Bayesian meta-analysis
Sa Ren, Janharpreet Singh, Sandro Gsteiger +8
The use of amyloid-beta (A) clearance to support regulatory approvals of drugs in Alzheimer's disease (AD) remains controversial. We evaluate A as a potential trial-level s…
Methods of multi-indication meta-analysis for health technology assessment: a simulation study
David Glynn, Pedro Saramago, Janharpreet Singh +4
A growing number of oncology treatments, such as bevacizumab, are used across multiple indications. However, in health technology assessment (HTA), their clinical and cost-effectiv…
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab
Sumayya Anwer, Janharpreet Singh, Sylwia Bujkiewicz +7
Background: Evidence maps have been used in healthcare to understand existing evidence and to support decision-making. In oncology they have been used to summarise evidence within…
Use of surrogate endpoints in health technology assessment: a review of selected NICE technology appraisals in oncology
Lorna Wheaton, Sylwia Bujkiewicz
Objectives: Surrogate endpoints, used to substitute for and predict final clinical outcomes, are increasingly being used to support submissions to health technology assessment agen…